How We Do It

Myelodysplastic syndromes: etiologies, evaluation, and therapy

Author and Disclosure Information

 

In this interview, Dr David Henry, MD, the Editor-in-Chief of JCSO, and David Steensma, MD, of the Dana-Farber Cancer Institute in Boston, talk about myelodysplasic syndromes, from diagnosis, evaluation, and etiologies, to therapy options and molecular sequencing.

Listen to the podcast below, or click on the PDF icon at the top of this introduction to read a transcript of the interview.​

Recommended Reading

Age and race affect access to myeloma treatment
MDedge Hematology and Oncology
Do industry payments increase prescribing for some targeted therapies?
MDedge Hematology and Oncology
Ponatinib bests older TKIs against Ph+ALL
MDedge Hematology and Oncology
Blinatumomab triggers complete MRD response in ALL
MDedge Hematology and Oncology
Generic antiemetic now available in US
MDedge Hematology and Oncology
Drug shows promise for treating AML, MDS
MDedge Hematology and Oncology
Gene variants linked to survival after HSCT
MDedge Hematology and Oncology
Duvelisib NDA granted priority review
MDedge Hematology and Oncology
Health Canada approves product for adult ALL
MDedge Hematology and Oncology
Team maps genetic evolution of T-ALL subtype
MDedge Hematology and Oncology